Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights to use CRISPR tech to create off-the-shelf cell therapy
Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights [...]
Exelixis nabs Merck veteran as chief medical officer on quest to expand its R&D footprint
Exelixis nabs Merck veteran as chief medical officer on quest [...]
Transatlantic VC veterans tap Novo Holdings to raise $124M rare disease fund
Transatlantic VC veterans tap Novo Holdings to raise $124M rare [...]
With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies
With $415M on the line, Genmab taps Synaffix for antibody-drug [...]
AstraZeneca taps Ionis to join crowd of companies gunning for rare heart disease in deal worth billions in biobucks
AstraZeneca taps Ionis to join crowd of companies gunning for [...]
Biogen-Eisai’s potential Aduhelm sequel drug granted speedy review by FDA
Biogen-Eisai’s potential Aduhelm sequel drug granted speedy review by FDA [...]
Editor’s Corner: Fierce Biotech’s top 10 most read stories in 2021
Editor’s Corner: Fierce Biotech’s top 10 most read stories in [...]
Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree
Novartis inks $800M upfront buyout of Gyroscope to continue eye [...]
Aiming to make 70 the new 50, Korify rolls out $100M longevity and mental health venture fund
Aiming to make 70 the new 50, Korify rolls out [...]
PhaseBio blames COVID-19 disruption as cardiovascular study axed
PhaseBio blames COVID-19 disruption as cardiovascular study axed aarmstrong Tue, [...]